Investment
Features
FeesSafety
Academy
More
Pluang+

Novo Resources to start 2,700m drilling at Tibooburra Gold Project in late Q3 2026 targeting high-grade gold zones.

Market News
29 Jul 2026
GlobeNewsWire
View Source
Bullish
Novo Resources to start 2,700m drilling at Tibooburra Gold Project in late Q3 2026 targeting high-grade gold zones.

Novo Resources is advancing exploration at the Tibooburra Gold Project in NSW through a joint venture with Manhattan Gold Corporation. A ~2,700 meter reverse circulation (RC) drilling program is planned to begin in late Q3 2026, focusing on the Clone and Pioneer South prospects, both known for high-grade gold mineralization. The drilling aims to extend known gold zones and test new targets identified through ongoing regional sampling and mapping. This program follows promising results from previous campaigns and is part of Novo's strategy to develop a significant gold resource in the historically under-explored Albert Goldfields area.

More News (NVO)

Biotech stocks and leveraged ETFs lead market declines amid volatile trading and clinical news.

Biotech stocks and leveraged ETFs lead market declines amid volatile trading and clinical news.

Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...

Market News
Bearish
6 hours ago
Novo Nordisk shares drop 7% as new targets fail to ease weight-loss drug market concerns

Novo Nordisk shares drop 7% as new targets fail to ease weight-loss drug market concerns

Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...

Market News
Bearish
15 hours ago
Novo Nordisk shares drop 7% after growth plan signals tougher competition ahead

Novo Nordisk shares drop 7% after growth plan signals tougher competition ahead

Novo Nordisk's stock fell 7% following its capital markets day where it outlined a growth plan that aligns with industry peers rather than exceeding them, signaling slower future growth. The company highlighted the upcoming loss of U.S. patent exclus...

Market News
Bearish
18 hours ago
Novo shares drop 7% after unveiling ambitious obesity drug growth plans through 2035

Novo shares drop 7% after unveiling ambitious obesity drug growth plans through 2035

Novo, a Danish pharmaceutical company, saw its shares fall up to 7% after announcing plans to launch over five new drugs with blockbuster potential by 2030 and targeting pipeline sales exceeding $23 billion by 2035. The company aims to grow revenue f...

Market News
Bearish
23 hours ago
Anthropic confirms it runs a wet biology lab to test AI-driven biology experiments in real life.

Anthropic confirms it runs a wet biology lab to test AI-driven biology experiments in real life.

Anthropic has revealed it operates a wet biology lab where its AI models conduct physical experiments, aiming to bridge AI theories with real-world biology. This lab functions like a typical biotech facility, supporting both in-house research and col...

Market News
Neutral
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App